Clinical Data Intellia finds genetic suspect for liver safety signals with ATTR gene therapy BioSpaceIn November 2025, one patient died after receiving Intellia Therapeutics' investigational gene silencer for transthyretin amyloidosis.Rare DiseaseRead full story pharminent August 7, 2026 (Last updated: August 8, 2026) BioSpace In November 2025, one patient died after receiving Intellia Therapeutics’ investigational gene silencer for transthyretin amyloidosis. Rare Disease Read full story Post navigation Previous: Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatmentsNext: Replimune Readies Launch of Newly Approved Melanoma Therapy Tudriqev Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026